MedPath

Clinical Evaluation of BackStop in Patients Undergoing Intraureteric Stone Lithotripsy

Not Applicable
Completed
Conditions
Renal Calculi
Kidney Stones
Interventions
Device: BackStop
Device: Intracorporeal lithotripsy without the use of an anti-retropulsion device
Registration Number
NCT00893282
Lead Sponsor
Pluromed, Inc.
Brief Summary

The purpose of this clinical study is to evaluate BackStop, a polymer-based device that is intended to be used during ureteroscopic lithotripsy to prevent retrograde stone migration. It is a water soluble polymer with reverse thermosensitive properties; the polymer exists as a liquid at low temperature (below 17 C) and rapidly transitions to a high viscosity gel at body temperature (i.e. in the ureter). BackStop is injected above the stones in the ureter and is intended to prevent retrograde migration of stones during ureteroscopic lithotripsy. Upon completion of the lithotripsy procedure, BackStop dissolves naturally or by irrigation.

The study hypothesis is that a greater proportion of patients will experience no retropulsion of a kidney stone when BackStop is used versus no anti-retropulsion device when undergoing intracorporeal lithotripsy.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
68
Inclusion Criteria
  • Patient with a solitary, radio-opaque ureteral stone in the proximal ureter.
  • Clinical indication for treatment by ureteroscopic lithotripsy.
  • Minimum 18 years old (or any institutional age limits for participation in clinical study).
  • Patients must be willing and able to participate in any follow-up visits, as required.
  • Patients must provide informed consent.
Exclusion Criteria

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
BackStopBackStopIntracorporeal lithotripsy with the use of an anti-retropulsion device.
ControlIntracorporeal lithotripsy without the use of an anti-retropulsion deviceNo anti-retropulsion device will be used during lithotripsy.
Primary Outcome Measures
NameTimeMethod
Ability of BackStop™ to minimize migration stone fragments in the proximal ureter will and reported as "yes" or "no".intra-operative
Secondary Outcome Measures
NameTimeMethod
Extent of residual fragments remaining in ureter at the follow-up visit 2 to 4 weeks post-procedure.one month
In the event that stone fragments migrate retrograde, there may be a need for the physician to employ additional proceduresone month

Trial Locations

Locations (1)

McGill University Health Center

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath